Cantrixil Phase I Study Progresses To Next Stage
SYDNEY, Oct. 10, 2018 /PRNewswire-AsiaNet/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the successful completion of Part A, the dose escalation component, of its phase I study of Cantrixil in ovarian canc...
Read more https://view-release/?pr-id=75661